A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for LIving FEtuses (ILIFE) trial
- PMID: 32907619
- PMCID: PMC7488113
- DOI: 10.1186/s13063-020-04716-1
A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for LIving FEtuses (ILIFE) trial
Abstract
Background: Undifferentiated connective tissue disease (UCTD) is known to induce adverse pregnancy outcomes and even recurrent spontaneous abortion (RSA) by placental vascular damage and inflammation activation. Anticoagulation can prevent pregnancy morbidities. However, it is unknown whether the addition of immune suppressants to anticoagulation can prevent spontaneous pregnancy loss in UCTD patients. The purpose of this study is to evaluate the efficacy of hydroxychloroquine (HCQ) and low-dose prednisone on recurrent pregnancy loss for women with UCTD.
Methods: The Immunosuppressant for Living Fetuses (ILIFE) Trial is a three-arm, multicenter, open-label randomized controlled trial with the primary objective of comparing hydroxychloroquine combined with low-dose prednisone and anticoagulation with anticoagulation alone in treating UCTD women with recurrent spontaneous abortion. The third arm of using hydroxychloroquine combined with anticoagulant for secondary comparison. A total of 426 eligible patients will be randomly assigned to each of the three arms with a 1:1:1 allocation ratio. The primary outcome is the rate of live births. Secondary outcomes include adverse pregnancy outcomes and progression of UCTD.
Discussion: This is the first multi-center, open-label, randomized controlled trial which evaluates the efficacy of immunosuppressant regimens on pregnancy outcomes and UCTD progression. It will provide evidence on whether the immunosuppressant ameliorates the pregnancy prognosis in UCTD patients with RSA and the progression into defined connective tissue disease.
Trial registration: ClinicalTrials.gov NCT03671174 . Registered on 14 September 2018.
Keywords: Hydroxychloroquine; Prednisone; Randomized controlled trial; Recurrent pregnancy loss; Recurrent spontaneous abortion; Undifferentiated connective tissue disease.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Comparing pregnancy outcomes in patients with Systemic Lupus Erythematosus (SLE) and Undifferentiated Connective Tissue Disease (UCTD): a descriptive cohort study.Rev Clin Esp (Barc). 2024 Jun-Jul;224(6):357-365. doi: 10.1016/j.rceng.2024.04.013. Epub 2024 Apr 24. Rev Clin Esp (Barc). 2024. PMID: 38670225
-
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.Cochrane Database Syst Rev. 2020 May 2;5(5):CD012852. doi: 10.1002/14651858.CD012852.pub2. Cochrane Database Syst Rev. 2020. PMID: 32358837 Free PMC article.
-
[Analysis of pregnancy outcomes, disease progression, and risk factors in patients with undifferentiated connective tissue disease].Beijing Da Xue Xue Bao Yi Xue Ban. 2023 Dec 18;55(6):1045-1052. doi: 10.19723/j.issn.1671-167X.2023.06.014. Beijing Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 38101787 Free PMC article. Chinese.
-
Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study.BMJ Open. 2019 Mar 20;9(3):e025649. doi: 10.1136/bmjopen-2018-025649. BMJ Open. 2019. PMID: 30898821 Free PMC article.
-
[Use of hydroxychloroquine in recurrent immune-mediated obstetric diseases (excluding systemic lupus): Scientific basis and evidence].Rev Med Interne. 2025 Apr;46(4):220-228. doi: 10.1016/j.revmed.2024.12.004. Epub 2024 Dec 27. Rev Med Interne. 2025. PMID: 39732523 Review. French.
Cited by
-
Long Noncoding RNA RP11-115N4.1 Promotes Inflammatory Responses by Interacting With HNRNPH3 and Enhancing the Transcription of HSP70 in Unexplained Recurrent Spontaneous Abortion.Front Immunol. 2021 Aug 13;12:717785. doi: 10.3389/fimmu.2021.717785. eCollection 2021. Front Immunol. 2021. PMID: 34484222 Free PMC article.
-
Efficacy of combining aspirin with hydroxychloroquine in pregnancies at high risk for pre-eclampsia: a prospective, multicentre, open-label, single-arm clinical trial, investigator-initiated study (HUGS study).BMJ Open. 2024 Dec 10;14(12):e081610. doi: 10.1136/bmjopen-2023-081610. BMJ Open. 2024. PMID: 39658277 Free PMC article. Clinical Trial.
-
Undifferentiated Connective Tissue Disease in Pregnancy: A Topic Yet to be Explored.Front Pharmacol. 2022 Jan 20;13:820760. doi: 10.3389/fphar.2022.820760. eCollection 2022. Front Pharmacol. 2022. PMID: 35126164 Free PMC article. Review.
-
A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database.Braz J Med Biol Res. 2024 Jul 29;57:e13392. doi: 10.1590/1414-431X2024e13392. eCollection 2024. Braz J Med Biol Res. 2024. PMID: 39082578 Free PMC article.
-
Hydroxychloroquine for preventing hypertensive pregnancy disorders in recurrent spontaneous abortion: a retrospective cohort study in a single referral center.Eur J Med Res. 2025 Apr 18;30(1):307. doi: 10.1186/s40001-025-02549-9. Eur J Med Res. 2025. PMID: 40251676 Free PMC article.
References
-
- Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol. 1999;17(5):615–620. - PubMed
-
- Vaz CC, Couto M, Medeiros D, Miranda L, Costa J, Nero P, et al. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol. 2009;28(8):915–921. - PubMed
-
- Guerrero LF, Rueda JC, Arciniegas R, Rueda JM. Undifferentiated connective tissue disease in a rheumatology center in Cali, Colombia: clinical features of 94 patients followed for a year. Rheumatol Int. 2013;33(4):1085–1088. - PubMed
-
- Spinillo A, Beneventi F, Ramoni V, Caporali R, Locatelli E, Simonetta M, et al. Prevalence and significance of previously undiagnosed rheumatic diseases in pregnancy. Ann Rheum Dis. 2012;71(6):918–923. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical